20:08 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Cell culture and mouse studies suggest a bispecific antibody against SLAMF7 and NKG2D could help treat SLAMF7-expressing MM. The bispecific antibody consists of a single-chain variable fragment (scFv) targeting SLAMF7 expressed...
22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
00:43 , Jun 29, 2018 |  BC Innovations  |  Product R&D

Highly personal

Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is...
22:55 , Jun 22, 2018 |  BC Extra  |  Preclinical News

Blocking LSD1 could activate cancer immune response via HERV

A Harvard Medical School team led by immunology and pathology professor Arlene Sharpe has shown inhibiting lysine-specific demethylase (LSD1; KDM1A) increases human endogenous retrovirus (HERV) transcription to activate an immune response that could help treat...
01:34 , Jun 22, 2018 |  BC Innovations  |  Targets & Mechanisms

T cell balancing act

Among the improvements to next-generation CAR T cell therapies is the need to optimize the ratios of the different T cell subsets. While CD8+ T cells have grabbed most of the attention, a study from...
21:10 , Jun 21, 2018 |  BC Innovations  |  Translation in Brief

Liver’s killer instinct

A study in Science suggests natural killer T cells residing in the liver uniquely position the organ to reap antitumor effects from antibiotic-mediated microbiome depletion, uncovering a novel link in the microbiome-cancer relationship that highlights...
19:13 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; melanoma Cell culture and mouse studies suggest adoptive transfer of IL-15-cultured T cells could help treat B7-H6 tumor cell ligand-positive cancers. CD8+ T cells derived from human donor blood and cultured for 12 days...
23:27 , Jun 14, 2018 |  BC Innovations  |  Tools & Techniques

Imaging immunotherapy

Stanford University researchers have made an imaging agent that detects activated T cells and could predict whether a patient will respond to immunotherapy within days of treatment. Typically, it takes weeks to months to determine...
18:19 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Mouse studies suggest ZFP36 inhibitors could help treat acute lymphocytic choriomeningitis virus (LCMV) infection. In a mouse model of acute LCMV infection, systemic ZFP36 knockout increased the number of LCMV-specific CD4+ T cells...
02:02 , Jun 9, 2018 |  BioCentury  |  Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together, data...